High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

References

• Russell NH. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev 1992;6:149–156.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 2007;26:6738–6749.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010;116:4251–4261.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003;24:659–666.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454–465.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Carapeti-Marootian M, Hochhaus A, et al. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 2002;99:1766–1775.
   PubMed Web of Science ®Google Scholar
• Haffner MC, Petridou B, Peyrat JP, et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 2007;7:136.
   PubMed Web of Science ®Google Scholar
• Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer 2012;118:761–769.
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654–3661.
   PubMed Web of Science ®Google Scholar
• Aronica MG, Brizzi MF, Dentelli P, et al. p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. Oncogene 1996;13:1017–1026.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, White SM, Schaefer TS, et al. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood 1996;88:2442–2449.
   PubMed Web of Science ®Google Scholar
• Biethahn S, Alves F, Wilde S, et al. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999;27:885–894.
   PubMed Web of Science ®Google Scholar
• Han L, Wierenga AT, Rozenveld-Geugien M, et al. Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One 2009;4:e7989.
   PubMed Web of Science ®Google Scholar
• Marvin J, Swaminathan S, Kraker G, et al. Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 2011;117:e120–e130.
   PubMed Web of Science ®Google Scholar
• Redell MS, Ruiz MJ, Alonzo TA, et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011;117:5701–5709.
   PubMed Web of Science ®Google Scholar
• Redell MS, Ruiz MJ, Gerbing RB, et al. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood 2013;121:1083–1093.
   PubMed Web of Science ®Google Scholar
• Piessevaux J, Lavens D, Montoye T, et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 2006;281:32953–32966.
   Google Scholar
• Tannahill GM, Elliott J, Barry AC, et al. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005;25:9115–9126.
   PubMedGoogle Scholar
• Metcalf D, Greenhalgh CJ, Viney E, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000;405:1069–1073.
   PubMed Web of Science ®Google Scholar
• Favre H, Benhamou A, Finidori J, et al. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 1999;453:63–66.
   PubMed Web of Science ®Google Scholar
• Greenhalgh CJ, Metcalf D, Thaus AL, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002;277:40181–40184.
   PubMed Web of Science ®Google Scholar
• Kazi JU, Ronnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol 2013;7:693–703.
   Google Scholar
• Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164–3173.
   PubMed Web of Science ®Google Scholar